Policy & Regulation
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the u...
Transgene expands myvac platform into non-small cell lung cancer with TG4070
22 June 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, i...
BioArctic and Eli Lilly enter BrainTransporter collaboration with up to USD800m in milestone payments
22 June 2026 - Swedish research-based biopharmaceutical company BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) reported on Monday that it has entered into a research and collaboration agreement with U...
Fusion Antibodies secures Canadian patent allowance for antibody library technology
22 June 2026 - Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) declared on Monday that it has received a notice of allowance from the Canadian Intellectual Property Offic...
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
22 June 2026 - Replicate Bioscience, a clinical-stage company developing novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic are...
Sanofi's Sarclisa SC formulation gains Japanese approval to treat multiple myeloma
22 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (i...